Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid Status

被引:129
作者
Carpenter, Thomas O. [1 ,3 ]
Insogna, Karl L. [2 ]
Zhang, Jane H. [4 ]
Ellis, Bruce [1 ]
Nieman, Sherril [3 ]
Simpson, Christine [2 ]
Olear, Elizabeth [1 ]
Gundberg, Caren M. [3 ]
机构
[1] Yale Univ, Sch Med, Dept Pediat Endocrinol, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Internal Med Endocrinol, New Haven, CT 06520 USA
[3] Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06520 USA
[4] Vet Afairs Connecticut Healthcare Syst, Vet Adm Cooperat Studies Program Coordinating Ctr, West Haven, CT 06516 USA
基金
美国国家卫生研究院;
关键词
CHRONIC KIDNEY-DISEASE; GROWTH-FACTOR; 23; ONCOGENIC OSTEOMALACIA; HYPERPARATHYROIDISM; FIBROBLAST-GROWTH-FACTOR-23; CALCITRIOL; RICKETS;
D O I
10.1210/jc.2010-0589
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Context: Circulating fibroblast growth factor (FGF)-23 is variably elevated in individuals with X-linked hypophosphatemia (XLH), and klotho has recently been shown to effect renal phosphate handling, yet limited data are available on circulating FGF23 and klotho in XLH. Objective: The objective of the study was to characterize circulating FGF23 and klotho in XLH. Design: Children and adults with XLH withheld medication for 14 d. Fasting serum FGF23, PTH, klotho, phosphate, and 1,25 dihydroxyvitamin D were obtained. Treated adults were also sampled, and circadian sampling was performed in selected individuals. Setting: The study was conducted at a hospital research unit at an academic medical center. Patients and Other Participants: Participants included 23 individuals with XLH and eight controls. Interventions: There were no interventions. Main Outcome Measures: Serum klotho and FGF23 were measured. Results: FGF23 was greater in XLH than in controls and greater in treated XLH subjects compared with XLH subjects not receiving medical therapy. Children had higher klotho levels than adults, but values in XLH were similar to controls. A strong positive correlation between FGF23 and PTH was found in XLH subjects, whereas there was no relationship between these variables in controls. Circulating klotho, but not FGF23, has a diurnal pattern. Conclusions: Serum klotho declines with age and demonstrates circadian variation but is normal in XLH. Serum FGF23 is similar in children and adults, is elevated in XLH, further increases with therapy, and demonstrates no diurnal variation. The direct relationship between FGF23 and PTH in subjects with XLH suggests that FGF23 regulation of PTH secretion is aberrant in this disorder. (J Clin Endocrinol Metab 95: E352-E357, 2010)
引用
收藏
页码:E352 / E357
页数:6
相关论文
共 13 条
[1]
Ardeshirpour Laleh, 2007, Pediatr Endocrinol Rev, V5 Suppl 1, P584
[2]
A translocation causing increased α-Klotho level results in hypophosphatemic rickets and hyperparathyroidism [J].
Brownstein, Catherine A. ;
Adler, Felix ;
Nelson-Williams, Carol ;
Iijima, Junko ;
Li, Peining ;
Imura, Akihiro ;
Nabeshima, Yo-ichi ;
Reyes-Mugica, Miguel ;
Carpenter, Thomas O. ;
Lifton, Richard P. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (09) :3455-3460
[3]
NOCTURNAL HYPERPARATHYROIDISM - A FREQUENT FEATURE OF X-LINKED HYPOPHOSPHATEMIA [J].
CARPENTER, TO ;
MITNICK, MA ;
ELLISON, A ;
SMITH, C ;
INSOGNA, KL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (06) :1378-1383
[4]
Oncogenic osteomalacia - A complex dance of factors [J].
Carpenter, TO .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17) :1705-1708
[5]
Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease [J].
Galitzer, H. ;
Ben-Dov, I. Z. ;
Silver, Justin ;
Naveh-Many, Tally .
KIDNEY INTERNATIONAL, 2010, 77 (03) :211-218
[6]
Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion [J].
Galitzer, Hillel ;
Ben-Dov, Iddo ;
Lavi-Moshayoff, Vardit ;
Naveh-Many, Tally ;
Silver, Justin .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2008, 17 (04) :363-367
[7]
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease [J].
Gutierrez, O ;
Isakova, T ;
Rhee, E ;
Shah, A ;
Holmes, J ;
Collerone, G ;
Jüppner, H ;
Wolf, M .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07) :2205-2215
[8]
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis [J].
Ichikawa, Shoji ;
Lmel, Erik A. ;
Kreiter, Mary L. ;
Yu, Xijie ;
Mackenzie, Donald S. ;
Sorenson, Andrea H. ;
Goetz, Regina ;
Moharnmadi, Moosa ;
White, Kenneth E. ;
Econs, Michael J. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (09) :2684-2691
[9]
Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 Concentrations [J].
Imel, Erik A. ;
DiMeglio, Linda A. ;
Hui, Siu L. ;
Carpenter, Thomas O. ;
Econs, Michael J. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (04) :1846-1850
[10]
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. [J].
Jonsson, KB ;
Zahradnik, R ;
Larsson, T ;
White, KE ;
Sugimoto, T ;
Imanishi, Y ;
Yamamoto, T ;
Hampson, G ;
Koshiyama, H ;
Ljunggren, Ö ;
Oba, K ;
Yang, IM ;
Miyauchi, A ;
Econs, MJ ;
Lavigne, J ;
Jüppner, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17) :1656-1663